Receptor tyrosine kinase inhibitors in thyroid cancer
Authors:
- Maria Domenica CastelloneMaria Domenica Castellone
- Francesca CarlomagnoFCFrancesca Carlomagno
- Giuliana SalvatoreGSGiuliana Salvatore
- Massimo SantoroMSMassimo Santoro
- 1 December 2008
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 22 (6) , 1023-1038
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Dysregulation of the Phosphatidylinositol 3-Kinase Pathway in Thyroid NeoplasiaEndocrinology and Metabolism Clinics of North America, 2008
- Role of platelet-derived growth factors in physiology and medicineGenes & Development, 2008
- siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinomaNucleic Acids Research, 2007
- A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrappingEndocrine-Related Cancer, 2007
- Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer ProgressionCancer Research, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Patterns of somatic mutation in human cancer genomesNature, 2007
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003